Lihua Zhang1, Linong Ji1, Lixin Guo2, Juming Lu3, Haoming Tian4, Dalong Zhu5, Xiaoping Xing6, Jian Ping Weng7, Weiping Jia8. 1. 1 Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China . 2. 2 Department of Endocrinology and Metabolism, Beijing Hospital , Beijing, China . 3. 3 Department of Endocrinology and Metabolism, Chinese PLA General Hospital , Beijing, China . 4. 4 Department of Endocrinology and Metabolism, Sichuan University West China Hospital , Chengdu, China . 5. 5 Department of Endocrinology and Metabolism, Nanjing Drum Tower Hospital , Jiangsu, China . 6. 6 Department of Endocrinology and Metabolism, Peking Union Medical College Hospital , Beijing, China . 7. 7 Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China . 8. 8 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai, China .
Abstract
BACKGROUND: Only a few studies have reported the use of oral antidiabetes drugs (OADs) for treating older adults with type 2 diabetes mellitus (T2DM) in China. This study assessed the status of OAD therapy and relevant factors associated with OAD treatment patterns and glycemic control among older patients. PATIENTS AND METHODS: We conducted a noninterventional, observational, cross-sectional, multicenter study, which was initiated by the Chinese Diabetes Society, in which 9,872 outpatients with T2DM were recruited who received OADs only. Current antidiabetes treatment regimens and related clinical data were collected from patients' self-reporting and medical records. Participants were divided into two groups: ≥65 years and <65 years. All data were tabulated, and statistical analyses were performed using SPSS version 16 software (SPSS Inc., Chicago, IL). RESULTS: Insulin secretagogues (52.6%): sulfonylureas (SU) (26.6%) and glinides (26.0%) were commonly used as monotherapy in those ≥65 years. The most popular OAD pattern was dual combination therapy (46.8%), with SU plus glucosidase inhibitors (25.1%) being most common in older participants. Age, diabetes duration, body mass index, achieving the glycemic control targets, and hypoglycemia were influencing factors to those ≥65 years in diverse treatment pattern models (P < 0.05). Older patients receiving OADs with triple or more combination treatment and complications were more likely to have substandard glycemic control (hemoglobin A1c level ≥7%). CONCLUSIONS: The pattern of OADs alone in older adults with T2DM was significantly different from those <65 years in China. A comprehensive OAD treatment pattern or insulin combination may be necessary for better glycemic control in older patients with multiple combinations of OADs or complications.
BACKGROUND: Only a few studies have reported the use of oral antidiabetes drugs (OADs) for treating older adults with type 2 diabetes mellitus (T2DM) in China. This study assessed the status of OAD therapy and relevant factors associated with OAD treatment patterns and glycemic control among older patients. PATIENTS AND METHODS: We conducted a noninterventional, observational, cross-sectional, multicenter study, which was initiated by the Chinese Diabetes Society, in which 9,872 outpatients with T2DM were recruited who received OADs only. Current antidiabetes treatment regimens and related clinical data were collected from patients' self-reporting and medical records. Participants were divided into two groups: ≥65 years and <65 years. All data were tabulated, and statistical analyses were performed using SPSS version 16 software (SPSS Inc., Chicago, IL). RESULTS: Insulin secretagogues (52.6%): sulfonylureas (SU) (26.6%) and glinides (26.0%) were commonly used as monotherapy in those ≥65 years. The most popular OAD pattern was dual combination therapy (46.8%), with SU plus glucosidase inhibitors (25.1%) being most common in older participants. Age, diabetes duration, body mass index, achieving the glycemic control targets, and hypoglycemia were influencing factors to those ≥65 years in diverse treatment pattern models (P < 0.05). Older patients receiving OADs with triple or more combination treatment and complications were more likely to have substandard glycemic control (hemoglobin A1c level ≥7%). CONCLUSIONS: The pattern of OADs alone in older adults with T2DM was significantly different from those <65 years in China. A comprehensive OAD treatment pattern or insulin combination may be necessary for better glycemic control in older patients with multiple combinations of OADs or complications.
Authors: Jiandong Zhou; Guoming Zhang; Carlin Chang; Oscar Hou In Chou; Sharen Lee; Keith Sai Kit Leung; Wing Tak Wong; Tong Liu; Abraham Ka Chung Wai; Shuk Han Cheng; Qingpeng Zhang; Gary Tse Journal: Acta Diabetol Date: 2022-02-03 Impact factor: 4.280